These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33863615)

  • 1. Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer.
    Punjabi A; Barrett E; Cheng A; Mulla A; Walls G; Johnston D; McAleese J; Moore K; Hicks J; Blyth K; Denholm M; Magee L; Gilligan D; Silverman S; Qureshi M; Clinch H; Hatton M; Philipps L; Brown S; O'Brien M; McDonald F; Faivre-Finn C; Hiley C; Evison M
    Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):e331-e338. PubMed ID: 33863615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 3. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
    Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neutrophil-to-lymphocyte ratio predicts the survival in patients with post-operative recurrence of non-small cell lung cancer].
    Wang X; Li K
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):298-302. PubMed ID: 24989918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of neutrophil-to-lymphocyte ratio change in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy.
    Yin X; Chen H; Sun Y; Xiao L; Lu H; Guo W; Yang H; Zhou J; Fan K; Liang W
    Sci Rep; 2024 May; 14(1):11984. PubMed ID: 38796631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study.
    Abravan A; Salem A; Price G; Faivre-Finn C; van Herk M
    Acta Oncol; 2022 Feb; 61(2):163-171. PubMed ID: 34979860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy.
    Sebastian N; Wu T; Bazan J; Driscoll E; Willers H; Yegya-Raman N; Bond L; Dwivedi A; Mo X; Tan Y; Xu-Welliver M; Haglund K; Jabbour SK; Keane FK; Williams TM
    Radiother Oncol; 2019 May; 134():151-157. PubMed ID: 31005209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
    Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
    PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study.
    Sawa A; Bando H; Kamohara R; Takeuchi N; Terasaki A; Okazaki M; Iguchi-Manaka A; Hara H
    Oncology; 2022; 100(11):591-601. PubMed ID: 36099888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.
    Yuan C; Li N; Mao X; Liu Z; Ou W; Wang SY
    Thorac Cancer; 2017 Jul; 8(4):350-358. PubMed ID: 28544400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil:lymphocyte ratio as a simple and novel biomarker for prediction of locoregional recurrence after chemoradiotherapy for squamous cell carcinoma of the anus.
    Toh E; Wilson J; Sebag-Montefiore D; Botterill I
    Colorectal Dis; 2014 Mar; 16(3):O90-7. PubMed ID: 24148256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-to-Lymphocyte Ratio Is Superior to Other Leukocyte-Based Ratios as a Prognostic Predictor in Non-Small Cell Lung Cancer Patients with Radiosurgically Treated Brain Metastases Under Immunotherapy or Targeted Therapy.
    Cho A; Kranawetter B; Untersteiner H; Khalaveh F; Dorfer C; Rössler K; Zöchbauer-Müller S; Gatterbauer B; Hochmair MJ; Frischer JM
    World Neurosurg; 2021 Jul; 151():e324-e331. PubMed ID: 33878466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
    Wang J; Liu Y; Mi X; Shao M; Liu L
    Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
    Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
    Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.
    Su MX; Lin HW; Nguyen HTH; Lin TC; Chen CJ; Wang HC; Wu CT; Wu YC; He GY; Liu LC; Huang CH
    BMC Cancer; 2024 Feb; 24(1):195. PubMed ID: 38347468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-lymphocyte ratio predicts recurrence in patients with resected stage 1 non-small cell lung cancer.
    Mizuguchi S; Izumi N; Tsukioka T; Komatsu H; Nishiyama N
    J Cardiothorac Surg; 2018 Jun; 13(1):78. PubMed ID: 29945635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial.
    Tokunaga E; Miyoshi Y; Dozono K; Kawaguchi T; Toi M
    Oncologist; 2024 Mar; 29(3):e319-e329. PubMed ID: 37971418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.